Ozempic and Alzheimer's, 23andMe's crisis, and Novo Nordisk wants a crackdown: Pharma news roundup
A new study found a link between NovoNordisk’s blockbuster drug Ozempic and a reduced risk of Alzheimer’s disease. 23andMe, the company that popularized consumer genetic testing, could soon be delisted from the Nasdaq.
The Danish drugmaker Novo Nordisk contends that semaglutide, the active ingredient in Ozempic and Wegovy, is too complex for ...
Novo Nordisk has asked the FDA to block production of compounded copies of Ozempic, arguing that it’s too difficult to do ...
Novo Nordisk wants the Food and Drug Administration (FDA) to prevent compounding pharmacies from manufacturing their own ...
Novo Nordisk just hit a technical red flag with a Death Cross, but its strong fundamentals suggest a potential rebound.
FDA recalls thousands of antidepressant bottles due to cancer-causing chemical{beacon} Health Care Health Care The Big ...
Novo Nordisk (NVO) has asked the FDA to ban cheap copies of its weight loss drugs Wegovy and Ozempic, arguing they pose safety risks, ...
Drugs such as Novo Nordisk's Ozempic and Eli Lilly's Mounjaro are approved to treat diabetes patients and have proven ...
Novo Nordisk CEO Lars Fruergaard Jorgensen has called attention to the complexities of the U.S. healthcare system while ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback